Status:
TERMINATED
Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence
Lead Sponsor:
Brain & Spine Surgeons of New York
Conditions:
Glioblastoma Multiforme
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is a phase 1b study for safety and tolerability of bevacizumab(Avastin)administered into the tumor resection cavity in subjects with Glioblastoma Multiforme (GBM) at first recurrence.
Eligibility Criteria
Inclusion
- Recurrent Glioblastoma
- At least 12 weeks expected survival (KPS \>60)
- 18 years of age or older
- Able and willing to participate
Exclusion
- Any prior diagnosis of any other cancer or other concurrent malignancy.
- Planned use or current use of other investigation therapy.
- Systemic autoimmune disease
- HIV positive
- Concurrent life threatening disease
- Impaired organ function
- Active infection
- Inadequately controlled hypertension
- Congestive heart failure
- Myocardial infection/unstable angina within 6 months
- Stroke within 6 months
- Pheripheral vascular disease
- History of abdominal fistula/gastrointestinal performation
- Non-healing wound
- Coagulation disease
- Known allergy to study treatments
- Pregnant or lactating
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT01526837
Start Date
October 1 2011
End Date
January 1 2012
Last Update
July 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brain & Spine Surgeons of New York
White Plains, New York, United States, 10604